证券研究报告 | 公司深度报告 2025 年 06 月 13 日 太龙药业（600222.SH） 国资赋能+集采放量，中药 CRO 打开第二曲线 | 财务指标 | 2023A | 2024A | 2025E | 2026E | 2027E | | --- | --- | --- | --- | --- | --- | | 营业收入（百万元） | 2,070 | 1,941 | 2,132 | 2,348 | 2,583 | | 增长率 yoy（%） | 5.6 | -6.2 | 9.8 | 10.1 | 10.0 | | 归母净利润（百万元） | 44 | 51 | 61 | 85 | 116 | | 增长率 yoy（%） | 160.3 | 16.0 | 21.5 | 38.4 | 36.5 | | ROE（%） | 2.8 | 3.3 | 3.9 | 5.0 | 6.4 | | EPS 最新摊薄（元） | 0.08 | 0.09 | 0.11 | 0.15 | 0.20 | | P/E（倍） | 80.9 | 69.7 | 57.4 | 41.5 | 30.4 | | P/B（倍） | 2.2 | 2.2 ...

Group 1 - Company GuoDeWei plans to repurchase shares with a total investment of between 100 million to 150 million yuan, with a maximum repurchase price of 53 yuan per share, expecting to buy back between 1.89 million to 2.83 million shares, accounting for 0.78% to 1.17% of total share capital [1] - Company Shuangliang Energy has won a bid for the Gansu Energy Chemical Qinyang 2×660MW coal power project, with a total bid amount of 237 million yuan, representing 1.82% of the company's projected revenue for 2024 [1] - Company China Pacific Insurance reported a total premium income of 227.17 billion yuan from its two subsidiaries in the first five months, with a year-on-year growth of 10.2% for its life insurance subsidiary and 0.5% for its property insurance subsidiary [1][2] Group 2 - Company LuKang Pharmaceutical has received a drug registration certificate for injectable Cefoperazone Sodium, a third-generation cephalosporin with broad-spectrum antibacterial properties [3] - Company 吉祥航空 reported a 4.97% year-on-year increase in passenger turnover in May, with a seat occupancy rate of 86.14%, up 3.70% year-on-year [4][5] - Company DuRui Pharmaceutical's subsidiary has also received a drug registration certificate for injectable Cefoperazone Sodium [6] Group 3 - Company KeLan Software announced that part of the shares held by its controlling shareholder will be auctioned, involving 5.09 million shares, accounting for 1.07% of the total share capital [7] - Company HuaCan Optoelectronics received a government subsidy of 87.84 million yuan, which is expected to positively impact the company's pre-tax profit for 2025 [8] - Company JinZhi Technology has won a bid for projects from the State Grid and China Resources New Energy, with a total bid amount of 84.41 million yuan [9] Group 4 - Company Vision China completed a capital increase for its subsidiary, raising 100 million yuan to accelerate its layout in the AI field [11] - Company Youa Co. received a profit distribution of 96.03 million yuan from its investment in Changsha Bank [13] - Company WanBangde's subsidiary obtained a patent for a deuterated compound, enhancing the chemical stability and reducing toxicity [16] Group 5 - Company DongCheng Pharmaceutical completed the enrollment of all 488 participants in the Phase III clinical trial for Fluorine-18 PSMA peptide injection, aimed at prostate cancer diagnosis [17] - Company China Merchants Expressway announced that its first phase of medium-term notes for 2024 will pay interest on July 2, 2025, with a total issuance of 2.5 billion yuan and an interest rate of 2.35% [18] - Company JinPu Titanium's subsidiary has temporarily suspended production for maintenance due to falling product prices and high production costs [20] Group 6 - Company BeiLu Pharmaceutical received a marketing authorization for Iodinated Contrast Injection in Hungary, marking another approval in the EU [22] - Company LiXing Co. obtained an overseas investment certificate for its wholly-owned subsidiary in Singapore, with a total investment of 2.16 million yuan [24] - Company LangKun Technology won a garbage collection service project with a bid amount of 21.57 million yuan [26] Group 7 - Company KeRui International plans to transfer 55% of its subsidiary Tianjin ZhiRui's equity for 41.96 million yuan [28] - Company Nanjing JuLong intends to invest 130 million yuan to build a production project for special materials with an annual output of 40,000 tons [30] - Company NanShan Intelligent plans to use up to 50 million yuan of idle funds for cash management in safe and liquid financial products [32] Group 8 - Company GuangLian Aviation completed the business change registration for its subsidiary, involving the introduction of strategic investors [34] - Company XiaoFang Pharmaceutical signed a cooperation agreement to develop a new drug for hair loss treatment [36] - Company GuiZhou SanLi plans to sign a 150 million yuan technology transfer and development contract with Guangdong Pharmaceutical University [38] Group 9 - Company ST SiLong's subsidiary received a drug registration certificate for Famotidine injection, used for treating upper gastrointestinal bleeding [52] - Company ZhongKe Information's executive plans to reduce holdings of up to 180,000 shares, accounting for 0.06% of total share capital [53] - Company KeLun Pharmaceutical's injectable Cefoperazone Sodium/Chloride Sodium injection received drug registration approval [54] Group 10 - Company LuXin Investment plans to transfer 10.06% of its stake in LuXin HuiJin for 203 million yuan, aiming to focus on its main business [56] - Company Western Gold plans to acquire 100% of Xinjiang MeiSheng for 1.655 billion yuan [58] - Company JinTou City Development intends to swap assets worth 5.862 billion yuan, changing its main business to urban centralized heating [60]

陕西博硕律师事务所 关于金花企业（集团）股份有限公司 差异化分红事项的法律意见书 致：金花企业（集团）股份有限公司 陕西博硕律师事务所（以下简称"本所"）接受金花企业（集团）股份有限 公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称 "《公司法》"）《中华人民共和国证券法》（以下简称"《证券法》"）《上 市公司股份回购规则》（以下简称"《回购规则》"）《上海证券交易所上市公 司自律监管指引第 7 号——回购股份》（以下简称"《第 7 号指引》"）等法律、 法规和规范性文件以及《公司章程》的规定，就公司 2024 年度利润分配所涉及 的差异化分红（以下简称"本次差异化分红"）相关事项进行了核查并出具本法 律意见书。 为出具本法律意见书，本所律师审阅了公司提供的本次差异化分红的相关文 件，就有关事项向公司进行了必要的询问。本所律师依据本法律意见书出具日以 前已经发生或存在的事实并基于对现行法律、法规和规范性文件的理解发表法律 意见。 本法律意见书仅就本次差异化分红所涉及到的法律问题发表法律意见，并不 对有关会计、审计、验资等专业事项和报告发表意见。本法律意见书中对有关审 计报告、验资报告中某 ...

Core Viewpoint - GuangYuYuan Chinese Herbal Medicine Co., Ltd. is preparing for its 2024 annual shareholders' meeting, focusing on maintaining shareholder rights and ensuring efficient proceedings [1][2][3]. Meeting Arrangements - The annual shareholders' meeting is scheduled for June 24, 2025, at 14:00 in Taiyuan, Shanxi [3]. - Shareholders must arrive 30 minutes early for registration and are limited to three minutes for speaking [2][3]. - Voting will occur both on-site and through internet platforms during specified time slots [3]. Agenda Items - The meeting will cover several key reports, including the 2024 annual work report from the board of directors, the supervisory board's report, financial statements, profit distribution plans, and independent directors' reports [3][4][5]. Board of Directors' Report - The board held six meetings during the reporting period, addressing various operational and financial matters, including accounting errors and annual reports [6][7]. - The company reported total assets of 2.276 billion and net assets of 1.570 billion as of December 31, 2024, with a revenue of 1.221 billion, a decrease of 4.87% year-on-year [13]. Operational Focus - The company emphasizes growth and operational efficiency, focusing on four core products and expanding its market presence through partnerships and new store openings [13][14]. - A cultural heritage strategy is in place to enhance brand influence, including collaborations with educational institutions and media [14][15]. Quality Assurance - The company is committed to high-quality production standards, implementing a comprehensive quality management system and collaborating with research institutions for innovation [15][16][20]. Governance and Compliance - The company is enhancing its governance structure, focusing on compliance and risk management, and has revised various internal regulations to ensure transparency and accountability [17][22][27]. Future Strategy - The company aims to strengthen its market position by leveraging its historical and cultural assets, enhancing brand visibility, and driving innovation through technology [19][21][22].

中国发展网讯 六月，荆门市掇刀区团林铺镇罗咀村迎来了一年中最忙碌且充满希望的时节——金银花 采收季。漫山遍野的金银花藤上，一簇簇青白相间的花苞挂满枝头，空气中弥漫着淡雅的清香，村民们 穿梭其中，忙着采摘这朵朵"金银"，勾勒出一幅生机勃勃的乡村丰收画卷。 金银花，又名忍冬，素有花中"高士"之称，凌冬不凋，春末夏初繁花满树，藤绽金银，不仅具有极高的 观赏价值，更是一味名贵的中药材，其经济价值也十分可观。 6月初的一个清晨，天刚蒙蒙亮，记者走进罗咀村，村口处早已热闹非凡。村民们三五成群，头戴遮阳 帽，手持大竹篮，脚步匆匆地朝着陈坡水库方向赶去。"去摘金银花嘞！"村民张传菊热情地向记者介绍 道。跟随她的脚步，记者来到了位于陈坡水库旁的金银花种植基地。雨后的基地，金银花藤蔓在微风中 轻轻摇曳，显得精神抖擞，那含苞待放的花苞，仿佛在等待着人们将它们采撷，转化为财富。 此时，稍早到达的村民已经熟练地开始了采摘工作。只见他们用指头精准地捏住花苞根部，掌心轻轻一 攒，随着"啪嚓"一声轻响，一大把花苞便收入竹篮。张传菊也迅速放好随身携带的小板凳，坐下投入采 摘。她动作娴熟、眼疾手快，不一会儿，竹篮就被装得满满当当。"这个品种的花 ...

Group 1 - The A-share market is experiencing downward pressure, with multiple signals indicating a potential decline, including prolonged high-level trading and low-volume rebounds [1] - The financial sector's ability to support the market is diminishing, with traditional giants like oil and coal taking over the role of market leaders, raising concerns about their effectiveness [2][5] - The white wine and automotive industries are facing challenges due to imbalanced production capacity, which is a core issue affecting these sectors [3] Group 2 - The pharmaceutical sector, including CROs and innovative drugs, has seen significant declines, indicating a downturn for previously popular stocks in this industry [4] - There is uncertainty regarding which sectors will lead the market recovery, with traditional weight sectors being questioned for their strength [5]

Group 1 - Guizhou Sanli plans to sign a technology transfer and development contract with Guangdong Pharmaceutical University, with a total contract amount of RMB 150 million [1] - The technology contract involves the transfer of a patent for the use of Jinlv Banfenghe in the preparation of drugs for liver injury prevention and treatment, along with other related patents [1][2] - The patent transfer was successfully completed for RMB 50 million, with the transaction taking place on June 11, 2025 [1] Group 2 - The contract stipulates an overall transfer fee of RMB 50 million for the patent rights, with an initial payment of RMB 5 million due within 10 working days after signing [2] - The total development cost for the technical cooperation is RMB 100 million, with payments to be made in installments based on contract terms [2]

Core Viewpoint - The stock of Kanghui Pharmaceutical experienced a significant drop, hitting the daily limit down, with a trading volume exceeding 150 million yuan [1] Group 1 - Kanghui Pharmaceutical's stock price fell to the daily limit, indicating a strong negative market reaction [1] - The trading volume for Kanghui Pharmaceutical surpassed 150 million yuan, reflecting heightened trading activity and investor interest [1]

Core Viewpoint - Yantai City is actively developing industrial tourism to cultivate new industrial momentum and expand tourism opportunities, transforming old industrial sites into cultural landmarks [2][3][4] Group 1: Industrial Tourism Development - Yantai has redefined tourism experiences, with young people increasingly visiting places like the Yantai Brewery for leisure activities [2] - The city is home to significant industrial heritage sites, including the Yantai Brewery and other historical factories, which are being repurposed as tourist attractions [2][3] - The local government aims to build a world-class cultural tourism city, achieving notable progress with multiple national and provincial industrial heritage sites [3] Group 2: Industrial Heritage and Cultural Significance - The transformation of old factories into cultural landmarks reflects the city's historical and emotional connections to its industrial past [2][3] - Yantai's industrial tourism is seen as a way to showcase the city's unique character and craftsmanship, emphasizing the importance of preserving industrial history [3] Group 3: New Tourism Products and Initiatives - The establishment of the first state-owned capital investment company, Guofeng Group, has led to the promotion of four industrial tourism routes, integrating various themes such as aerospace and marine resources [4] - These new tourism products aim to attract both domestic and international visitors, enhancing the overall tourism landscape in Yantai [4]

这究竟是合理财务调整，还是掩盖竞争力下降、资产质量恶化的"会计魔术"？ 作者 | beyond 编辑 | 小白 2024年最新财报显示，步长制药（603858.SH，公司）营业收入110亿元，同比下降17%；归母净利润 亏损5.5亿元，同比下降274%。 | | | | 单位:元 币种:人民币 | | | --- | --- | --- | --- | --- | | 主要会计数据 | 2024年 | 2023年 | 本期比上年 同期增减(%) | 2022年 | | 营业收入 | 11.005.794.900.15 | 13.245.133.303.78 | -16.91 | 14,951,252,694.46 | | 扣除与主营业务无关的业务收 入和不具备商业实质的收入后 | 10, 973, 732, 093. 81 | 13, 228, 514, 200. 82 | -17.04 | 14.941.635.462.12 | | 的营业收入 | | | | | | 归属于上市公司股东的净利润 | -553.797.938.80 | 318, 973, 324. 80 | -273.62 | -1.529 ...